Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 17/20 | 0.47 |
| ▸ | DRD2 | P14416 | 11/20 | 0.47 |
| ▸ | HTR7 | P34969 | 9/20 | 0.47 |
| ▸ | HTR6 | P50406 | 7/20 | 0.47 |
| ▸ | HTR2A | P28223 | 7/20 | 0.47 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | HTR1D | P28221 | 5/20 | 0.43 |
| ▸ | HTR2C | P28335 | 5/20 | 0.43 |
| ▸ | HTR2B | P41595 | 5/20 | 0.43 |
| ▸ | HTR5A | P47898 | 5/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686245 | 0.86 | HTR1A (0.59) | HTR1ADRD2HTR7 | |
| SCHEMBL4686300 | 0.86 | DRD2 (0.46) | HTR1ADRD2HTR7HTR6HTR2A | |
| SCHEMBL5208574 | 0.83 | DRD2 (0.53) | HTR1ADRD2HTR7HTR6HTR2A | |
| SCHEMBL4925377 | 0.78 | DRD2 (0.44) | HTR1ADRD2HTR7HTR6HTR2A | |
| SCHEMBL4684336 | 0.77 | DRD3 (0.61) | HTR1ADRD2HTR7HTR2ADRD3 | |
| SCHEMBL4685461 | 0.77 | DRD2 (0.57) | HTR1ADRD2HTR7HTR6HTR2A | |
| SCHEMBL8220195 | 0.77 | HTR1A (0.62) | HTR1ADRD2HTR7HTR6HTR2A | |
| SCHEMBL4687018 | 0.76 | DRD2 (0.62) | HTR1ADRD2HTR7HTR6HTR2A | |
| SCHEMBL4684354 | 0.75 | — | — | |
| SCHEMBL2783112 | 0.74 | DRD2 (0.49) | HTR1ADRD2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828125-B1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET SOC CIV (FR) | 2008-04-09 | — | — | EP | claimed |
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | BIOPROJET (FR) | 2008-09-04 | — | — | US | disclosed |
| EP-1828125-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006058993-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANDS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | SLC6A3, ADRB3, PRLHR | HTR1A 88/4885DRD2 8/4885HTR7 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.